0000000000284307

AUTHOR

Alessio Piraino

showing 5 related works from this author

Why small particle fixed dose triple therapy? An excursus from COPD pathology to pharmacological treatment evolution

2022

Although bronchodilators are the cornerstone in chronic obstructive pulmonary disease (COPD) therapy, the treatment with a single-agent bronchodilator may not provide adequate symptoms control in COPD. The combination of drugs with different mechanisms of action may be more effective in inducing bronchodilation and preventing exacerbations, with a lower risk of side-effects in comparison with the increase of the dose of a single molecule. Several studies comparing the triple therapy with the association of long-acting ß2 agonist (LABA)/inhaled corticosteroid (ICS) or long-acting muscarinic antagonist (LAMA)/LABA reported improvement of lung function and quality of life. A significant reduc…

Pulmonary and Respiratory MedicineRC705-779ReviewMuscarinic AntagonistsSettore MED/10 - Malattie Dell'Apparato RespiratorioCOPD inhaled extrafine formulation triple therapyinhaled extrafine formulationBronchodilator AgentsDrug CombinationsPulmonary Disease Chronic ObstructiveDiseases of the respiratory systemtriple therapyFormoterol FumarateAdministration InhalationQuality of LifeCOPDHumansDrug Therapy CombinationPharmacology (medical)Adrenergic beta-2 Receptor AgonistsTherapeutic Advances in Respiratory Disease
researchProduct

Extracorporeal shock waves increase markers of cellular proliferation in primary bronchial fibroblasts of COPD patients

2019

COPD is due to a remodeling of small airways and destruction of the lung parenchyma with loss of the alveolar attachment as a result of pulmonary emphysema. Treatment of connective tissue fibroblasts with extracorporeal shock waves (ESW) increases their cellular proliferation and differentiation. To date no studies are available on ESW treatment of human primary bronchial fibroblasts from COPD and control subjects. Primary bronchial fibroblasts were obtained from bronchial biopsies from three patients with mild/moderate COPD and 3 control smokers with normal lung function. After stabilization for 24h, 1 ml of cell suspension (106 cells) from COPD and controls was treated in 2 ml tubes with …

COPDPathologymedicine.medical_specialtybiologybusiness.industryCell growthCD117Connective tissuemedicine.diseaseExtracorporealrespiratory tract diseasesProliferating cell nuclear antigenmedicine.anatomical_structureParenchymabiology.proteinMedicineCD90businessAirway pharmacology and treatment
researchProduct

Extracorporeal Shock Waves Increase Markers of Cellular Proliferation in Bronchial Epithelium and in Primary Bronchial Fibroblasts of COPD Patients

2020

Chronic obstructive pulmonary disease (COPD) is due to structural changes and narrowing of small airways and parenchymal destruction (loss of the alveolar attachment as a result of pulmonary emphysema), which all lead to airflow limitation. Extracorporeal shock waves (ESW) increase cell proliferation and differentiation of connective tissue fibroblasts. To date no studies are available on ESW treatment of human bronchial fibroblasts and epithelial cells from COPD and control subjects. We obtained primary bronchial fibroblasts from bronchial biopsies of 3 patients with mild/moderate COPD and 3 control smokers with normal lung function. 16HBE cells were also studied. Cells were treated with a…

Extracorporeal Shockwave TherapyMalePathologyPulmonary Disease Chronic Obstructive0302 clinical medicineMedicine0303 health sciencesCOPDSmokersbiologyCell DifferentiationMiddle AgedProto-Oncogene Proteins c-kitmedicine.anatomical_structurepsychological phenomena and processesResearch ArticlePulmonary and Respiratory MedicineExtracorporeal Shock Waves COPDCell typemedicine.medical_specialtyArticle SubjectPrimary Cell CultureeducationConnective tissueBronchibehavioral disciplines and activitiesCollagen Type ICell LineTransforming Growth Factor beta1Diseases of the respiratory system03 medical and health sciencesProliferating Cell Nuclear AntigenParenchymaHumansCD90RNA MessengerAgedCell Proliferation030304 developmental biologyRC705-779business.industryCD117Cell growthTranscription Factor RelAEpithelial CellsFibroblastsmedicine.diseaserespiratory tract diseasesProliferating cell nuclear antigen030228 respiratory systemCase-Control Studiesbiology.proteinbusiness
researchProduct

<p>Day and Night Control of COPD and Role of Pharmacotherapy: A Review</p>

2020

The topic of 24-hour management of COPD is related to day-to-night symptoms management, specific follow-up and patients' adherence to therapy. COPD symptoms strongly vary during day and night, being worse in the night and early morning. This variability is not always adequately considered in the trials. Night-time symptoms are predictive of higher mortality and more frequent exacerbations; therefore, they should be a target of therapy. During night-time, in COPD patients the supine position is responsible for a different thoracic physiology; moreover, during some sleep phases the vagal stimulation determines increased bronchial secretions, increased blood flow in the bronchial circulation (…

medicine.medical_specialtyCOPDEveningbusiness.industryGeneral MedicineDiseasemedicine.diseaseSleep medicinerespiratory tract diseases03 medical and health sciences0302 clinical medicinePharmacotherapy030228 respiratory systemBronchiolitisInternal medicinemedicine030212 general & internal medicinebusinessDynamic hyperinflationAsthmaInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Day and Night Control of COPD and Role of Pharmacotherapy: A Review

2020

Abstract The topic of 24-hour management of COPD is related to day-to-night symptoms management, specific follow-up and patients’ adherence to therapy. COPD symptoms strongly vary during day and night, being worse in the night and early morning. This variability is not always adequately considered in the trials. Night-time symptoms are predictive of higher mortality and more frequent exacerbations; therefore, they should be a target of therapy. During night-time, in COPD patients the supine position is responsible for a different thoracic physiology; moreover, during some sleep phases the vagal stimulation determines increased bronchial secretions, increased blood flow in the bronchial circ…

nightLABAReviewMuscarinic AntagonistsSettore MED/10 - Malattie Dell'Apparato Respiratoriocopd – symptoms – dyspnea – night – sleep – follow-up – adherence – circadian lama – laba – icsAdherence; Circadian; COPD; Dyspnea; Follow-up; Night; Sleep; SymptomsPulmonary Disease Chronic ObstructiveAdrenal Cortex HormonesAdministration InhalationSettore MED/10follow-upCOPDHumansadherencesleepAdrenergic beta-2 Receptor Agonistslcsh:RC705-779Circadianlcsh:Diseases of the respiratory systemdyspnearespiratory tract diseasesBronchodilator Agentscircadian LAMAICSsymptomsAdherence Circadian COPD Dyspnea Follow-up Night Sleep SymptomsInternational Journal of COPD
researchProduct